Piper Sandler Assumes TCR2 Therapeutics (TCRR) at Overweight
- Second half starts with fresh strain on stocks
- Goldman Sachs Warns Clients of More Equity Market Losses in Second Half of 2022
- Kohl's (KSS) Falls 15% After Ending Sale Talks With Franchise Group and Issuing Q2 Warning
- General Motors Warns It Has 95k Vehicles in Inventory Without Certain Components
- FAAMG Stocks Fall 32% on Average During 1st-Half of 2022
Piper Sandler analyst Do Kim assumes coverage on TCR2 Therapeutics (NASDAQ: TCRR) with a Overweight rating and a price target of $26.00.
Shares of TCR2 Therapeutics closed at $6.60 yesterday.
You May Also Be Interested In
- UPDATE: Citi Starts Symbotic Inc. (SYM) at Buy
- TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer
- Autonomous Research Starts Upstart Holdings Inc (UPST) at Underperform
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!